Full-Time

Associate Director

Risk Management and Centralized Monitoring

Posted on 4/16/2025

Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$168k - $210k/yr

+ Incentive Cash + Stock Opportunities

Senior

Company Historically Provides H1B Sponsorship

Uxbridge, UK + 2 more

More locations: Princeton, NJ, USA | San Diego, CA, USA

The job may require in-person presence at one of the listed locations, indicating a hybrid work model.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Data Analysis
Google Cloud Platform
Requirements
  • A minimum of a bachelor’s degree in one of the following disciplines or related field: Life Sciences (preferred); Analytics; Data Science; Statistics; Business; is required.
  • At least 8 years in the pharmaceutical industry with sound understanding of drug development and 5 years of experience in clinical trial operations and/or Good Clinical Practice is expected.
  • Significant expertise in Risk-Based Monitoring principles (Quality by Design, Risk Assessment & Control) and relevant tools (e.g RACT, risk analytics platforms, Veeva and other quality systems)
  • Technical expert in data analysis and interpretation using data visualizations to derive meaningful insights; and an ability to effectively tell the story of the data findings
  • Ability to lead the development and implementation of data visualizations and analyses to support Risk Management / Central Monitoring business needs.
  • Expertise in GCP, compliance and regulatory expectations with significant experience of audits and health authority inspections, root cause analysis and CAPA.
  • Outstanding Leadership skills with an ability to influence and manage key internal stakeholders (including senior leadership) as well as external stakeholders (including Health Authorities).
  • Excellent communication, collaboration and teamwork skills with an ability to drive cross-functional stakeholders (including senior leaders) to consensus and resolve conflict in a constructive manner.
  • Ability to understand organizational and industry direction, anticipate future trends, opportunities, and challenges and adjust strategies accordingly.
  • Open mindset with an ability to be flexible, responsive, and proactive in addressing new challenges, opportunities, and demands.
  • Ability to articulate a clear, compelling vision for change that inspires and motivates others.
Responsibilities
  • AD is accountable for ensuring a high quality and consistent Protocol De-risking process is applied to studies within their portion of the portfolio, resulting in a robust Integrated Risk Management Plan (IRMP) which is maintained and kept relevant throughout the lifecycle of the study
  • AD ensures a high quality and consistent holistic data review strategy is applied to studies within their portion of the portfolio, resulting in a robust Integrated Data Review Plan (IDRP)
  • Responsible for regular risk monitoring for their allocated portion of the portfolio and providing a holistic risk report at the agreed frequency.
  • Ensure appropriate escalations of emerging risks (including QTL deviations) to the relevant governance committee (e.g. Quality Council/Therapeutic Area leadership) and proactively shares knowledge and insights across the CORM group.
  • Connects the outcomes of Risk Review Meetings of studies within their portion of the portfolio to their additional risk analyses in order to feed into higher level risk logs via a compelling ‘risk story’ at asset/portfolio/TA level
  • Lead or contribute to the development and maintenance of metrics that inform the evaluation of risk monitoring performance and effectiveness.
  • Leadership or participation in large strategic initiatives / continuous improvement opportunities within the CORM and broader organizations
  • Drive and support the strategic direction of Risk Based Management within the business to include leadership of RBM innovation (including representing the Company in interactions with key external partners as part of any committee or industry group relating to RBM), education and embedding
  • Ensure effective quality oversight and management of external partners (e.g. Function Service Providers, CROs, technology providers, etc.) performing Risk Management or Central Monitoring activities on behalf of BMS
  • Develop strong and productive working relationships with key stakeholders throughout TDS, GDO, and BMS with the ability to think strategically across a broad portfolio and effectively express his/her views to senior management
  • Coach, mentor and develop new team members.
  • Develop and promote a workplace culture that values diversity of thought, promotes integrity and creates an atmosphere that supports coaching and fosters accountability
  • Takes on additional responsibilities as directed by leadership.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery accelerates BMS's R&D, improving drug development efficiency.
  • BMS's acquisition of 2seventy bio enhances its cancer cell therapy capabilities.
  • Positive Phase 3 trial results for Sotyktu boost BMS's psoriatic arthritis treatment portfolio.

What critics are saying

  • Increased competition in oncology may impact BMS's market share.
  • Layoffs could decrease employee morale, affecting operational efficiency.
  • Integration challenges from acquiring 2seventy bio may pose financial risks.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases, setting it apart in biopharma.
  • The company integrates AI in early lung cancer diagnosis, enhancing precision care.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

European HHHM
Apr 16th, 2025
Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis

Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has entered an agreement with Bristol Myers Squibb (NYSE: BMY), to leverage AI in early diagnosis and precision lung cancer care.

CMMB
Mar 24th, 2025
Our Values, Your Impact

In partnership with Bristol Myers Squibb, Catholic Medical Mission Board Inc. is playing a role in building the infrastructure and workforce to bring quality cancer care to rural Kenya.

PR Newswire
Mar 20th, 2025
Bristol Myers Squibb Appoints Osama Braiwish As General Manager For Saudi Arabia Gulf Countries

RIYADH, Saudi Arabia, March 20, 2025 /PRNewswire/ -- Bristol Myers Squibb, a leading global biopharmaceutical company, has recently appointed Osama Braiwish as its General Manager for Saudi Arabia and Gulf Countries, an affiliate covering Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan

Investors Hangout
Mar 20th, 2025
Bristol Myers Squibb Welcomes New Leadership in Gulf Region

Bristol Myers Squibb, a leader in the global biopharmaceutical sector, has appointed Osama Braiwish as its General Manager for the Gulf region, thereby enhancing its capacity to serve medical needs across various specialties.

Business Wire
Mar 12th, 2025
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all

INACTIVE